About US
Contact us
-
Endo caves to FDA pressure, will pull Opana ER from the marketUnder pressure from the FDA, Endo has decided to pull from the market its opioid painkiller Opana ER, a drug that generated nearly $160 million in sales last year. The Dublin-based drugmakersaidthat2017/6/28
-
Forget Sanofi's Zika shot. A new measure would limit pricing on all DOD-funded medicationThe controversy over Sanofi's eventual pricing for an in-development Zika vaccine might just spawn pricing constraints for all treatments developed with the help of Defense Department funding. Under2017/6/25
-
Is 2017 set to be the year we see a CAR-T therapy approved? Let’s find out from the leaders in the fieldUsing your body’s own cells, engineering them to target tumors and cure cancer sounds like something from a Sci-Fi movie but it’s not, it’s happening right now!CAR-TandTCRtherapies have taken theimm2017/6/24
-
Trial deaths frustrate Merck's bid to pair Keytruda with Celgene's myeloma starsAfter reviewing deaths in two Keytruda trials, the FDA put both Merck studies on clinical hold and stopped Keytruda dosing in a third, thwarting Merck's hopes for combining Keytruda with Celgene's big2017/6/23
-
Amgen, Teva hikes show pharma can't blame rebates for all price increases: analystPharma companies and pharmacy benefit managers have engaged in a back-and-forth for months over who’s to blame for high drug prices. Drugmakers say they're raising prices largely to keep ahead of PBMs2017/6/22
-
Lions Health versus mainstream Lions: are they really different breeds?ByRachel McCready, Klick Health; Creative Strategist Having just wrapped its fourth year, theCannes Lions Healthcompetition is still finding its identity. With the ever-expanding definition of health2017/6/21
-
With its €5.3B buyout scuppered, Stada brings in new CEO, CFOAfter failing to win the shareholder support needed to complete a €5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helm2017/6/18
-
Lilly’s Olumiant, spurned by FDA, gets nod from NICEEli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a modicum of good news for a drug the FDA rejected in April. England’s cost watchdog, in final guida2017/6/17
-
Bayer stops production of Gynera contraceptive in BrazilBrazilian authorities, which earlier ordered drugmaker Bayer to pull its Essure birth control device from the market, have now asked for the recall of more than a dozen lots of a Bayer birth control p2017/6/16
-
As Congress battles over healthcare, Johnson & Johnson CEO says real reform will take time—and cooperationWhile Republican senators work feverishly on a healthcare bill, one prominent pharma CEO says overhauling the system won't take a few weeks of work. Think years, even decades—and he'd like Democrats t2017/6/15